ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1541

Tofacitinib versus Belimumab in maintenance therapy of Systemic Lupus Erythematosus: A Real-World Study of the CSTAR cohort

(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1098

Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring

(1088–1122) Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 1095

Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series

(1088–1122) Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 1228

Transcending barriers to pain care in rural America: a pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain

(1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: Abstract Number: 1309

Transcriptomic biomarkers of progression from undifferentiated arthritis to rheumatoid arthritis

(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

10:30AM-10:45AM: Abstract Number: 0893

Transcriptomic insights into GCA compared to clinically diverse controls: Inflammation, Aging, Therapeutic Targets and the role of SPP1 in the temporal artery

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA From Bench to Bedside (0891–0896)

10:30AM-12:30PM: Abstract Number: 1213

Transitional Changes on High Resolution Computed Tomography (HRCT) in idiopathic inflammatory Myopathy- Associated Interstitial Lung Disease (IIM-ILD)

(1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1403

Treatment of sleep apnoea syndrome in patients with primary Sjögren’s disease improves symptoms and activity of disease

(1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

10:30AM-12:30PM: Abstract Number: 1372

Treatment Patterns and Outcomes After Janus Kinase Inhibitor Discontinuation in Rheumatoid Arthritis: A Real-World Cohort Study

(1347–1375) Rheumatoid Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1552

Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study

(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1031

Trends and Gender Disparities in Rheumatoid Arthritis Burden in the United States: A Population-Based Time-Trend Analysis Using the Global Burden of Disease Database, 1990–2021

(1007–1037) Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1053

Trends in Cost and Utilization of Biologic Medications for Rheumatologic Conditions: A Medicare Claims Study (2013–2022)

(1038–1054) Health Services Research Poster II

10:30AM-12:30PM: Abstract Number: 1407

Trends in Diagnostic Timing and Clinical Features of Axial Spondyloarthritis by Sex and Clinical Subtype: A Multicenter Cohort Over Seven Decades

(1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1078

Trends in Hospitalization rate with Lupus in the State of Florida: A retrospective data review from Florida Health Charts from 1992-2023

(1055–1087) Healthcare Disparities in Rheumatology Posters

10:30AM-12:30PM: Abstract Number: 1320

Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study

(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].